Inside the FDA Peptide Advisory Committee: What to Expect at the July 23–24 PCAC Meeting

The FDA’s Pharmacy Compounding Advisory Committee will convene at the FDA White Oak Campus in Silver Spring, Maryland on July 23–24, 2026 to evaluate whether seven peptides should be added to the Section 503A bulks list — the list that determines which substances compounding pharmacies can legally use.

Day 1 (July 23, 8:00 AM – 4:30 PM ET): BPC-157 (body protection compound), KPV (anti-inflammatory tripeptide), TB-500 (thymosin beta-4 fragment), MOTS-c (mitochondrial open reading frame of 12S rRNA-c)

Day 2 (July 24, 8:00 AM – 3:50 PM ET): Emideltide/DSIP (delta sleep-inducing peptide), Semax (synthetic ACTH fragment), Epitalon (synthetic epithalamin tetrapeptide)

The meeting includes a public comment period. Interested parties can submit written comments through the established FDA docket or request to speak during the open public hearing portion of the meeting.

The PCAC currently has 6 of 10 seats vacant: the chairperson, the consumer representative, three voting member positions, and one industry representative slot. Only three voting members and one industry representative remain.

This is raising significant concern among public health advocates. Public Citizen, a consumer advocacy organization, warned that the vacancies could be filled before July with appointees who would "rubber stamp" broader peptide access — similar to what critics allege happened with the Advisory Committee on Immunization Practices at the CDC.

STAT News reported on April 29, 2026 that the committee composition could determine the outcome: a full committee with traditional FDA scientific standards might vote differently than one stacked with members sympathetic to the view that peptide restrictions are overly paternalistic.

The FDA has not publicly announced new PCAC appointments. The timing of any appointments relative to the July 23–24 meeting will be closely watched.

The strength of clinical evidence varies dramatically across the seven peptides:

BPC-157: Extensive animal data showing tissue repair, wound healing, and anti-inflammatory effects. No published human randomized controlled trials. The most commercially significant peptide on the agenda. First human safety trial initiated in 2026.

TB-500: Animal data on tissue repair, cell migration, and anti-inflammation. No published human RCTs. Often used alongside BPC-157 for recovery.

KPV: Tripeptide derived from alpha-MSH. Anti-inflammatory effects shown in cell studies and animal models, particularly for gut inflammation. Very limited clinical data.

MOTS-c: Mitochondrial-derived peptide with metabolic effects in animal models. Improves insulin sensitivity and exercise capacity in mice. No published human trials. WADA-banned substance.

Semax: The strongest clinical evidence on the agenda. Approved as a prescription medication in Russia for cognitive and cerebrovascular conditions. Multiple human studies, though primarily from Russian literature.

Epitalon: Studied for telomerase activation in cell culture and animal models. Limited human data, primarily from Russian research groups.

DSIP/Emideltide: Sleep-modulating peptide identified in the 1970s. Human studies exist but are dated and methodologically limited by modern standards.

The July PCAC meeting exists because of a chain of political decisions. In February 2026, Health Secretary RFK Jr. told Joe Rogan he intended to make peptides more accessible. In March, his department directed the FDA to reconsider peptide restrictions. In April, the FDA removed 12 peptides from Category 2 (the "safety concern" list) and scheduled the PCAC review.

The debate breaks along predictable lines. Supporters argue that peptides like BPC-157 and TB-500 have decades of safety data, that patients should have access to compounds their physicians prescribe, and that the original 2023 restrictions were overly broad.

Critics argue that most of these peptides lack adequate human safety and efficacy data from controlled trials, that the regulatory process should be driven by science rather than political pressure, and that compounding pharmacies lack the manufacturing controls of FDA-approved facilities.

The outcome will set a precedent for how the FDA evaluates bulk drug substances for compounding access — particularly when political pressure and public demand are strong but controlled clinical evidence is limited.

Between now and July 23, several developments will signal how the vote is likely to go:

New PCAC appointments. Any new members appointed before the meeting will indicate the administration’s approach. Appointees with backgrounds in integrative medicine or compounding pharmacy would suggest a favorable lean; appointees with traditional pharmaceutical regulatory backgrounds would suggest a more cautious approach.

Public comment submissions. The volume and nature of public comments in the FDA docket will indicate the level of organized advocacy. The compounding pharmacy industry and peptide advocacy groups are expected to submit extensive comments.

BPC-157 human trial data. Any preliminary safety data from the BPC-157 human clinical trial initiated in 2026 could influence the committee’s assessment.

The 503B decision timeline. How the FDA handles the separate 503B proposal to ban compounded GLP-1s could signal the agency’s broader posture toward compounding.